Saturday, September 20, 2025

A case of #H10N3 avian #influenza in a young woman

 


Context and significance

The avian influenza A virus subtype H10N3 is a possible candidate for causing a fatal flu and may present a serious public health threat. Research increasingly shows that the avian influenza virus H10N3 can be transmitted from birds to humans, causing severe viral pneumonia and potentially leading to acute respiratory distress syndrome and respiratory failure. Researchers at the Fourth People’s Hospital of Nanning (China) provide evidence supporting the cross-species transmission of the avian influenza virus H10N3 to humans, which can give rise to severe pneumonia. The authors report that a female patient with avian influenza virus H10N3 infection, who was suffering from severe pneumonia, respiratory failure, pneumothorax, and numbness and dysesthesia in her feet, recovered after receiving appropriate therapy and was discharged from the hospital.


Highlights

• A young woman contracted the avian influenza virus H10N3

• Secondary infections, pneumothorax, and foot numbness developed consecutively

• Baloxavir marboxil and oseltamivir were administered


Summary

Background

Avian influenza viruses, frequently identified in wild waterfowl and poultry, have occasionally been transmitted to humans, causing severe respiratory diseases. This report covers the fourth case of a human contracting the H10N3 subtype of avian influenza virus.

Methods

A case of novel avian influenza virus subtype H10N3 was detected in a female patient hospitalized in Nanning, China, in December 2024. Blood, feces, urine, and bronchoalveolar lavage fluid were collected from the patient for medical analysis during the hospitalization.

Findings

A case of novel avian influenza virus subtype H10N3 was detected in a female patient hospitalized in Nanning, China, in December 2024. She also had a history of exposure to live poultry. This case represents the fourth documented instance of H10N3 infection in humans. She was treated with a combination of baloxavir marboxil and oseltamivir. She exhibited extensive lung lesions. Additionally, she presented complicating factors, including secondary infection, pneumothorax, and numbness in her feet. She recovered and was discharged on March 27, 2025, amid comprehensive supportive care, which included therapy with baloxavir marboxil, oseltamivir, fluconazole, tigecycline, amikacin, extracorporeal membrane oxygenation, and rehabilitation therapy.

Conclusions

The virus was effectively cleared by the combination therapies. The internal genes of the H10N3 virus in this patient were highly homologous to the corresponding genes from the A/Yunnan/2024 virus (GenBank accession numbers, hemagglutinin [HA] [GenBank: PP555669] and PB-2 [GenBank: PP555666]).

Funding

This work was funded by the Fourth People’s Hospital of Nanning - Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS) Clinical Treatment Center of Guangxi (Nanning).

Source: Med., https://www.cell.com/med/abstract/S2666-6340(25)00272-7

____

History of Mass Transportation: RhB Ge 6/6 Rhaetian Crocodile Electric Locomotive (1921)

 


Von JoachimKohlerBremen - Eigenes Werk, CC BY-SA 4.0, https://commons.wikimedia.org/w/index.php?curid=50664108

Source: Wikipedia, https://de.wikipedia.org/wiki/Schweizerische_Lokomotiv-_und_Maschinenfabrik

____

#Coronavirus Disease Research #References (by AMEDEO, September 20 '25)

 


    J Infect

  1. GRANVIK C, Persson IL, Barros GWF, Ahlm C, et al
    Long-term Physical Capacity Following COVID-19: A Prospective, Three-Year Study.
    J Infect. 2025 Sep 12:106614. doi: 10.1016/j.jinf.2025.106614.
    PubMed         Abstract available


    J Med Virol

  2. BADAR N, Salman M, Ahad A, Mirza HA, et al
    Tracking SARS-CoV-2 Lineages in Pakistan's 2025 COVID-19 Resurgence: Insights From Genomic Surveillance.
    J Med Virol. 2025;97:e70607.
    PubMed        

  3. LIU S, Shao C, Ding Y, Wang Y, et al
    Ubiquitination: A Double-Edged Mechanism in Coronavirus Infections.
    J Med Virol. 2025;97:e70589.
    PubMed         Abstract available


    J Virol

  4. CHIOK KL, Jenik K, Fenton M, Falzarano D, et al
    MERS-CoV and SARS-CoV-2 infection in diverse human lung organoid-derived cultures.
    J Virol. 2025 Sep 18:e0109825. doi: 10.1128/jvi.01098.
    PubMed         Abstract available

  5. JIAN X, Hu T, Xu H, Wen Y, et al
    An orally available 4'-fluorouridine prodrug inhibits SFTSV and LCMV infection.
    J Virol. 2025 Sep 16:e0117225. doi: 10.1128/jvi.01172.
    PubMed         Abstract available

  6. FARRUKEE R, Mordant F, Mackenzie-Kludas C, Mesner D, et al
    Human guanylate-binding protein (GBP) 1 inhibits replication of severe acute respiratory syndrome coronavirus 2.
    J Virol. 2025 Sep 15:e0082325. doi: 10.1128/jvi.00823.
    PubMed         Abstract available

  7. WANG J, Sang X, Zheng W, Chan JF-W, et al
    Discovery of a potent covalent inhibitor that unusually distorts the catalytic dyad of SARS-CoV-2 main protease.
    J Virol. 2025 Sep 15:e0065825. doi: 10.1128/jvi.00658.
    PubMed         Abstract available

  8. YANG L, Qian Q, Sun Y-g, Chen X-x, et al
    PEDV Nsp14 induces mitophagy-mediated degradation of MAVS to antagonize host innate immunity and facilitate viral proliferation.
    J Virol. 2025;99:e0049825.
    PubMed         Abstract available


    Science

  9. COHEN J
    Florida plan to nix vaccine mandates raises alarm.
    Science. 2025;389:1075-1076.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, September 20 '25)

 


    Ann Intern Med

  1. FELDMAN CH, Santacroce L, Bassett IV, Thaweethai T, et al
    Social Determinants of Health and Risk for Long COVID in the U.S. RECOVER-Adult Cohort.
    Ann Intern Med. 2025 Jul 29. doi: 10.7326/ANNALS-24-01971.
    PubMed         Abstract available


    Arch Virol

  2. PUENPA J, Dara S, Vichaiwattana P, Aeemjinda R, et al
    Seasonal dynamics and genetic diversity of human rhinoviruses in patients with acute respiratory infection in Bangkok in 2024.
    Arch Virol. 2025;170:208.
    PubMed         Abstract available


    J Gen Virol

  3. DI GENOVA C, Warren CJ, Johnson S, Riccio S, et al
    Pigeons exhibit low susceptibility and poor transmission capacity for H5N1 clade 2.3.4.4b high pathogenicity avian influenza virus.
    J Gen Virol. 2025;106.
    PubMed         Abstract available

  4. PHAN N, Zaytseva Y, Lin CC, Mishra M, et al
    PUM2 binds SARS-CoV-2 RNA and PUM1 mildly reduces viral RNA levels, but neither protein affects progeny virus production.
    J Gen Virol. 2025;106:002152.
    PubMed         Abstract available


    J Infect

  5. AHIMBISIBWE G, Greenwood D, Wilkinson KA, Gahir J, et al
    Third exposure to COVID-19 infection or vaccination differentially impacts T Cell responses.
    J Infect. 2025 Aug 21:106598. doi: 10.1016/j.jinf.2025.106598.
    PubMed         Abstract available

  6. LIU B, Song S, Liu W, Hu Y, et al
    Post-COVID-19 multimorbidity incidence by prior vaccination status in people with a pre-existing comorbidity: A population-based cohort study.
    J Infect. 2025;91:106597.
    PubMed         Abstract available

  7. ATTAIANESE F, Trapani S, Agostiniani R, Ambrosino N, et al
    Effectiveness of a targeted infant RSV immunization strategy (2024-2025): A multicenter matched case-control study in a high-surveillance setting.
    J Infect. 2025;91:106600.
    PubMed         Abstract available

  8. DIETL B, Henares D, Cuchi E, Blanco-Fuertes M, et al
    Differential nasopharyngeal microbiota patterns: A Comparative Study of Pneumococcal Pneumonia, COVID-19, and Healthy Adults.
    J Infect. 2025 Aug 14:106589. doi: 10.1016/j.jinf.2025.106589.
    PubMed         Abstract available

  9. LI Z, Wang X, Chen S, Xiong W, et al
    Assessing Global Border Controls in Response to COVID-19 Pandemic Using Real-World Data and Target Trial Emulation.
    J Infect. 2025 Aug 12:106578. doi: 10.1016/j.jinf.2025.106578.
    PubMed         Abstract available

  10. JANANI L, Munro APS, Wright A, Aley PK, et al
    Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: results from COV-BOOST trial.
    J Infect. 2025 Aug 7:106576. doi: 10.1016/j.jinf.2025.106576.
    PubMed         Abstract available

  11. SYMES R, Keddie SH, Walker J, McKeever T, et al
    Burden of respiratory syncytial virus infection in older adults hospitalised in England during 2023/24.
    J Infect. 2025;91:106570.
    PubMed         Abstract available

  12. GONZALEZ-SANCHEZ A, Andres C, Prats-Mendez I, Pinana M, et al
    Evolutionary dynamics of HRSV following the implementation of nirsevimab immunoprophylaxis in Catalonia (2023-2024).
    J Infect. 2025;91:106567.
    PubMed         Abstract available


    J Virol

  13. PAPPAS C, Brock N, Belser JA, Kieran TJ, et al
    Identification of clinical and virological correlates associated with influenza A candidate vaccine virus (CVV) attenuation in a ferret model.
    J Virol. 2025 Sep 17:e0102325. doi: 10.1128/jvi.01023.
    PubMed         Abstract available

  14. LI Q, Cai X, Li X, Zhang Y, et al
    Structural and functional constraints on spike activation and host protease utilization limit cell entry of SARS-CoV-2-related bat coronaviruses.
    J Virol. 2025 Jul 24:e0100725. doi: 10.1128/jvi.01007.
    PubMed         Abstract available

  15. XU Z, Li L, Gu Y, Li D, et al
    CX1/BtSY2 and BANAL-20-52 exhibit broader receptor binding and higher affinities to multiple animal ACE2 orthologs than SARS-CoV-2 prototype.
    J Virol. 2025 Jul 10:e0028325. doi: 10.1128/jvi.00283.
    PubMed         Abstract available


    PLoS One

  16. CHOI MJ, Choi WS, Song JY, Cheong HJ, et al
    Estimating the clinical and economic burden of medically attended influenza in South Korea, stratified by age and comorbidity: A five-season hospital-based surveillance data, 2014/15-2018/19.
    PLoS One. 2025;20:e0317643.
    PubMed         Abstract available

  17. EI D, Bradvik G, Lindgren P, Barach P, et al
    Correlations between the prescribing patterns of psychotropic medications and socio-economic factors during the COVID-19 pandemic: A cross-sectional Swedish registry study.
    PLoS One. 2025;20:e0330081.
    PubMed         Abstract available

  18. MARFOH K, Samba A, Okyere E, Fattah AZ, et al
    Post-vaccination SARS-CoV-2 infections among healthcare workers in a tertiary hospital in Ghana.
    PLoS One. 2025;20:e0331971.
    PubMed         Abstract available

  19. BELSHAW Z, Brand CL, O'Neill DG, Packer RMA, et al
    More than just one man and his dog: The many impacts of puppy acquisition on the mental health of families including children in the UK.
    PLoS One. 2025;20:e0331179.
    PubMed         Abstract available

  20. CETIN S, Ulgen A, Sivgin H, Cetin M, et al
    Osmolality as a strong predictor of COVID-19 mortality and its possible links to other biomarkers.
    PLoS One. 2025;20:e0331344.
    PubMed         Abstract available

  21. SUN Y, Yang C
    The influence of investor sentiment on the Chinese stock market amid COVID-19: An event study analysis.
    PLoS One. 2025;20:e0332216.
    PubMed         Abstract available

  22. GIANCOLA M, Mari E, Palmiero M, Burrai J, et al
    Adolescence and online vulnerability: The role of fear of missing out (FoMO): A cross-sectional study during the third wave of the COVID-19 pandemic.
    PLoS One. 2025;20:e0332147.
    PubMed         Abstract available

  23. HE Y, Cheng C, Wang L
    Unmasking the effects of E-leadership on virtual team effectiveness by an integrated fsQCA and NCA method.
    PLoS One. 2025;20:e0331500.
    PubMed         Abstract available

  24. FAZZIO I, Shivalli S, Magill N, Elbourne D, et al
    Support To Rural India's Public Education System (STRIPES2) and impact on numeracy and literacy scores: A cluster randomized trial in rural villages of Madhya Pradesh, India.
    PLoS One. 2025;20:e0330203.
    PubMed         Abstract available

  25. PENG J, Isoni A, Luckman A, Zeitoun H, et al
    How facemasks shape trust in social interactions.
    PLoS One. 2025;20:e0331918.
    PubMed         Abstract available

  26. VISHKIN A, Bkheet E
    Effects of survey administration mode on response profiles are predictable, and robust across countries: Evidence from 29 countries using machine-learning models.
    PLoS One. 2025;20:e0330182.
    PubMed         Abstract available

  27. HERNAWAN B, Duran-Sierra GF, Zarate-Losoya E, Medina-Cetina Z, et al
    A pandemic risk index to improve supply chains decision-making between US and Mexico: A COVID-19 case study.
    PLoS One. 2025;20:e0327526.
    PubMed         Abstract available

  28. TERAKAWA K, Katagiri D, Asai Y, Ishikane M, et al
    A retrospective cohort study evaluating the predictive value of urinary L-FABP combined with the SOFA score for assessing COVID-19 severity.
    PLoS One. 2025;20:e0331558.
    PubMed         Abstract available

  29. WANJIKU P, Orindi B, Kimotho J, Sayed S, et al
    Induction of an early IFN-gamma cellular response and high plasma levels of SDF-1alpha are inversely associated with COVID-19 severity and residence in rural areas in Kenyan patients.
    PLoS One. 2025;20:e0316967.
    PubMed         Abstract available

  30. LI Y, Lu X, Fu J, Yang F, et al
    Influence of SARS-CoV-2 infection before and during organogenesis on embryo implantation and development outcomes: A prospective cohort observational study.
    PLoS One. 2025;20:e0328743.
    PubMed         Abstract available

  31. CLAVERIE D, Duffaud A, Pellissier S, Jacob S, et al
    Influence of mindfulness and coping flexibility in the early phases of burnout development in intensive care unit healthcare workers during the COVID-19 pandemic.
    PLoS One. 2025;20:e0328064.
    PubMed         Abstract available

  32. YOON CS, Park HY, Park HK, Lee JK, et al
    The influence of pneumococcal positivity on clinical outcomes among patients hospitalized with COVID-19: A retrospective cohort study.
    PLoS One. 2025;20:e0329474.
    PubMed         Abstract available

  33. BONILLA Y, High D, Acosta Rullan J, Tabba J, et al
    Body mass index and critical care outcomes in hospitalized COVID-19 patients-A national cohort study.
    PLoS One. 2025;20:e0329779.
    PubMed         Abstract available

  34. WASILEWSKI MB, Leighton J, Reis L, Vijayakumar A, et al
    Coping with stressful life disruptions due to long COVID: A qualitative study.
    PLoS One. 2025;20:e0329831.
    PubMed         Abstract available

  35. TCHOUA PP, Patel S, Starr AS, Rairigh R, et al
    Implementation of oral health evidence-based practices in early care education settings across the U.S. during different COVID-19 periods.
    PLoS One. 2025;20:e0323396.
    PubMed         Abstract available

  36. GUTMANIS I, Coleman BL, Ramsay K, Maunder R, et al
    Changes in emotional distress among Ontario education workers during the COVID-19 pandemic: 2021-2023.
    PLoS One. 2025;20:e0330442.
    PubMed         Abstract available

  37. HERNANDEZ GT, Menendez D, Yoo SH, Klapper RE, et al
    "What happens when you get corona?": Children's questions and parental responses about the COVID-19 pandemic.
    PLoS One. 2025;20:e0330506.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  38. SWINGLE KL, Hamilton AG, Han X, Liao KC, et al
    Circular RNA lipid nanoparticle vaccine against SARS-CoV-2.
    Proc Natl Acad Sci U S A. 2025;122:e2505718122.
    PubMed         Abstract available

  39. URMI T, Pant B, Dewey G, Quintana-Mathe A, et al
    Characterizing population-level changes in human behavior during the COVID-19 pandemic in the United States.
    Proc Natl Acad Sci U S A. 2025;122:e2500655122.
    PubMed         Abstract available


    Vaccine

  40. SHEN Y, Sung MH, Ge Y, Chen Y, et al
    Predicting influenza vaccine-elicited antibody responses with practical point systems.
    Vaccine. 2025;64:127737.
    PubMed         Abstract available

  41. ODAGIRI T, Yoshino N, Sasaki Y, Ishikawa S, et al
    Polymyxin B as a novel mucosal adjuvant for the intranasal whole inactivated influenza vaccine.
    Vaccine. 2025;64:127750.
    PubMed         Abstract available

  42. LANE A, Quach HQ, Ovsyannikova IG, Kennedy RB, et al
    High-resolution antibody dynamics following influenza vaccination reveal predominantly weak responses as well as infrequent but durable immunity across the 2014-2022 seasons.
    Vaccine. 2025 Sep 12:127677. doi: 10.1016/j.vaccine.2025.127677.
    PubMed         Abstract available

  43. OKOLI GN, Murphy C, Mak L, Cheng SMS, et al
    Estimates of SARS-CoV-2 vaccine effectiveness against outpatient medically attended SARS-CoV-2 infection from April 2023 through August 2024 in Hong Kong: A test-negative design study.
    Vaccine. 2025;63:127687.
    PubMed         Abstract available

  44. DEGIUSEPPE JI
    Comprehensive assessment of the impact of universal rotavirus vaccination program on the burden of diarrheal disease in children after 10 years of implementation in Argentina.
    Vaccine. 2025;63:127681.
    PubMed         Abstract available

  45. MORGAN JC, Kornides ML, Lee J, Fishman J, et al
    Different vaccination debunking interventions: a randomized, controlled experiment estimating "backfiring" and positive effects.
    Vaccine. 2025;62:127463.
    PubMed         Abstract available

  46. HATZL S, Posch F, Schulz E, Uhl B, et al
    Altered immune responses to mRNA vaccination against SARS-COV-2 are characterized by an impaired cross-talk between humoral and T-cellular immune compartments in patients with hematologic diseases.
    Vaccine. 2025;63:127666.
    PubMed         Abstract available

  47. KITAMURA N, Tomo Y, Okuyama M, Ueda K, et al
    COVID-19 vaccine effectiveness and duration of protection among children and adolescents: A retrospective cohort study in 11 large cities in Japan.
    Vaccine. 2025;63:127656.
    PubMed         Abstract available

  48. FU JYL, Syed Omar SF, Rajasuriar R, Kukreja A, et al
    Longitudinal dynamics of immune responses after mRNA and inactivated COVID-19 vaccination, boosters, and breakthrough infections in Malaysia.
    Vaccine. 2025;63:127657.
    PubMed         Abstract available

  49. COSGROVE S, Hider P, Anglemyer A, Walls T, et al
    HPV vaccination in Aotearoa New Zealand: Impact of a school-based program on adolescent vaccine coverage.
    Vaccine. 2025;63:127637.
    PubMed         Abstract available

  50. KORVES C, Kulldorff M, Balajee AS, Smith J, et al
    Innovative use of self-controlled methods for the evaluation of waning effectiveness of the COVID-19 monovalent third dose: comparison with a test-negative design.
    Vaccine. 2025;63:127658.
    PubMed         Abstract available

  51. WARD JK, Youssef R, Peretti-Watel P
    Different vaccines, different trust issues? Disentangling the effect of trust in various institutions using dominance analysis.
    Vaccine. 2025;63:127668.
    PubMed         Abstract available

  52. LI G, Marchevsky NG, Macaulay G, Aley P, et al
    Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006).
    Vaccine. 2025;62:127597.
    PubMed         Abstract available

  53. GROOM HC, Kuntz JL, Varga AM, Smith N, et al
    Parental intent to vaccinate children with the updated 2023-2024 COVID-19 vaccine.
    Vaccine. 2025;63:127618.
    PubMed         Abstract available

  54. LOUTH J, Holland A, Chum C, Morgan L, et al
    Understanding the immunity gap for serogroup B invasive meningococcal disease due to non-pharmaceutical interventions during the Covid-19 pandemic.
    Vaccine. 2025;63:127647.
    PubMed         Abstract available

  55. CIESLA AA, Mak J, Godoshian A, Smith ZR, et al
    Symptom reporting and vaccination status among SARS-CoV-2-positive encounters - Increasing Community Access to Testing, Treatment, and Response program, United States, September 2023-August 2024.
    Vaccine. 2025;63:127635.
    PubMed         Abstract available

  56. BRUCKER A, Hurst JH, O'Brien EC, Anderson D, et al
    An analytic approach considering two temporal mechanisms driving breakthrough viral infections after vaccination.
    Vaccine. 2025;63:127638.
    PubMed         Abstract available

  57. TSCHERNE A, Sun W, Liu STH, Krammer F, et al
    Mucosal COVID-19 vaccines in clinical development.
    Vaccine. 2025;63:127602.
    PubMed         Abstract available

  58. LUONG NGUYEN LB, Magloire L, Francois A, Billard D, et al
    Humoral immune response to Covid-19 vaccination in patients with cancer - Results from the ANRS0001S COV-POPART study.
    Vaccine. 2025;63:127633.
    PubMed         Abstract available

  59. SHAW CA, Stewart-Jones GBE, Jorquera P, Narayanan E, et al
    Design and preclinical assessment of mRNA-1345 prefusion F glycoprotein-encoding mRNA vaccine for respiratory syncytial virus.
    Vaccine. 2025;63:127589.
    PubMed         Abstract available

  60. KARRAS J, Harrison M, Danchin M, Kaufman J, et al
    Supporting dialogue amongst multicultural communities: Exploring the role of vaccine champions.
    Vaccine. 2025;63:127629.
    PubMed         Abstract available

  61. MORSTEAD T, Loo N, Sin NL, DeLongis A, et al
    COVID-19 hoax belief endorsement and its implications for vaccine uptake: Investigating the role of perceived threat.
    Vaccine. 2025;63:127630.
    PubMed         Abstract available

  62. BUHL C, Jacobsen R, Traulsen JM, Andersen A, et al
    Validation of the Danish translation of the vaccination attitudes examination (VAX) scale.
    Vaccine. 2025;62:127620.
    PubMed         Abstract available

  63. VARISKALLIO S, Moustgaard H, Remes H, Martikainen P, et al
    Association of parental education with adolescents' COVID-19 vaccine uptake: A nationwide register-based study in Finland.
    Vaccine. 2025;63:127615.
    PubMed         Abstract available

  64. GOLLUB EL, Myszkowski N, Xi M, Boyraz G, et al
    Correlates of higher trust in public health officials: results from a representative cohort of private university undergraduates.
    Vaccine. 2025;63:127610.
    PubMed         Abstract available

  65. JEONG NY, Cho S, Lim E, Lee JR, et al
    COVID-19 vaccination and the risk of abnormal uterine bleeding: A nationwide self-controlled case series study.
    Vaccine. 2025;63:127619.
    PubMed         Abstract available

  66. IZQUIERDO G, Villena R, Cabrera C, Albornoz J, et al
    Safety of timely immunization with nirsevimab in hospitalized preterm infants.
    Vaccine. 2025;63:127591.
    PubMed         Abstract available

  67. BAUR C, Saperstein SL, Griffis RL, Vazquez C, et al
    Implementing a co-design approach to facilitate a COVID-19 vaccination rapid response.
    Vaccine. 2025;62:127585.
    PubMed         Abstract available

  68. LINDSEY KM, Farrell Z, Tutino R, Kowalski-Dobson T, et al
    From first infection to reinfection: Comparing Nucleocapsid antibody kinetics in vaccinated and unvaccinated adults.
    Vaccine. 2025;62:127593.
    PubMed         Abstract available

  69. VARMA A, Andrews NJ, Carazo S, Walter K, et al
    Analytical approaches and examples of addressing time-varying factors in COVID-19 vaccine effectiveness studies: Report from a meeting of the World Health Organization.
    Vaccine. 2025;62:127567.
    PubMed         Abstract available

  70. ROBERTS C, Top KA, Henaff L, Tunis M, et al
    Exploring off-label vaccine use: a survey of the global national immunization technical advisory group network.
    Vaccine. 2025;62:127581.
    PubMed         Abstract available

  71. BHAT S, Basak P, Verma S, Siddiqui K, et al
    Type 2 diabetes compromises SARS-CoV-2-specific immunological memory following ChAdOx1 nCoV-19 vaccination.
    Vaccine. 2025;62:127604.
    PubMed         Abstract available

  72. HUNTER OF, McClymont E, Lau O, Bettinger JA, et al
    Knowledge gaps and research priorities regarding vaccination in pregnancy: A Canadian perspective from the prevention of infections in the maternal-infant dyad (PRIMED) consortium.
    Vaccine. 2025;62:127594.
    PubMed         Abstract available

  73. LUVIRA V, Lawpoolsri S, Phumratanaprapin W, Jongkaewwattana A, et al
    Immune responses to a heterologous booster with mRNA based COVID-19 vaccine after priming with an inactivated Newcastle disease virus recombinant vaccine expressing the SARS-CoV-2 spike protein (NDV-HXP-S).
    Vaccine. 2025;62:127601.
    PubMed         Abstract available

  74. VASILIADIS S, Cook J, Nissan K, Cook W, et al
    Vaccine misinformation among Arabic-speakers in Australia and the audience and appetite for a game-based intervention.
    Vaccine. 2025;62:127599.
    PubMed         Abstract available

  75. KILLANDER MOLLER I, Hedberg P, Wagner P, Sparen P, et al
    Sociodemographic factors influencing SARS-CoV-2 vaccination uptake in people with and without HIV: Insights from a Swedish Nationwide cohort.
    Vaccine. 2025;62:127580.
    PubMed         Abstract available

  76. NUZHATH T, Khobragade N, Regan AK, Pinkney JA, et al
    Pregnant women's perceptions of RSVpreF vaccine and Nirsevimab for infant RSV prevention.
    Vaccine. 2025;62:127590.
    PubMed         Abstract available

  77. IMHOF C, Liu S, Messchendorp AL, Sanders JF, et al
    The phenotype and functionality of spike-specific CD4(+) T cells after COVID-19 vaccination associates with time after transplantation in transplant recipients.
    Vaccine. 2025;62:127600.
    PubMed         Abstract available

  78. JAYARAJ VJ, Husin M, Tok PSK, Ismail MZH, et al
    Assessing the relative vaccine effectiveness of a fourth COVID-19 dose on hospitalization in Malaysia amidst evolving omicron variants: An emulated target trial.
    Vaccine. 2025;62:127569.
    PubMed         Abstract available

  79. SIU JY
    Barriers to COVID-19 vaccinations and moral struggle among nurses in a Chinese community: A critical medical anthropology analysis.
    Vaccine. 2025;62:127574.
    PubMed         Abstract available

  80. LIDSTROM AK, Albinsson B, Sund F, Lindback J, et al
    Adverse drug reactions following SARS-CoV-2 vaccination of 3805 healthcare workers cause substantial sick-leave and are correlated to vaccine regimen, age, sex and serological response.
    Vaccine. 2025;62:127553.
    PubMed         Abstract available

  81. AHSAN F, Rahmawati NY, Dachlan EG, Alditia FN, et al
    Memory T cell reactivity to a broad range of conserved SARS-CoV-2-derived ORF1ab epitopes in first wave COVID-19 convalescents.
    Vaccine. 2025;62:127571.
    PubMed         Abstract available

  82. OSMENAJ T, van Roon A, Labuschagne L, Pijpers J, et al
    Determinants for not keeping up to date with COVID-19 vaccination in the 2023 vaccination round among medical risk groups, the Netherlands.
    Vaccine. 2025;62:127561.
    PubMed         Abstract available

  83. XU S, Sy LS, Contreras R, Powers DA, et al
    Differences in COVID-19 XBB.1.5 vaccination coverage: A decomposition analysis across racial and ethnic groups in a large U.S. healthcare system.
    Vaccine. 2025;62:127577.
    PubMed         Abstract available

  84. KURIYAMA K, Murakami K, Sugiura K, Sakui S, et al
    One-year follow-up of the immunogenicity and safety of a first and second booster dose of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Final report of a phase 3 ope
    Vaccine. 2025;62:127562.
    PubMed         Abstract available

  85. MORO PL, Getahun A, Romanson B, Marquez P, et al
    Safety monitoring of Pfizer's Respiratory Syncytial Virus Vaccine in pregnant women in the Vaccine Adverse Event Reporting System (VAERS), 2023-2024, United States.
    Vaccine. 2025;62:127497.
    PubMed         Abstract available

  86. SCAIOLI G, Martella M, Moro GL, Mara A, et al
    Assessing vaccination intentions and perceptions among pregnant women in Italy: A multicenter cross-sectional study in the context of mandatory policies and the COVID-19 pandemic.
    Vaccine. 2025;62:127528.
    PubMed         Abstract available

  87. FORTUNATO F, Martinelli D, Ascatigno L, Campanozzi A, et al
    Cost of universal immunization with Nirsevimab vs. standard of practice for infants in their first RSV season. Foggia District, Italy, 2023-2024.
    Vaccine. 2025;62:127550.
    PubMed         Abstract available

  88. MOREIRA J, Patino EG, Braga PE, Pacheco P, et al
    Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac) in Brazilian healthcare professionals: The PROFISCOV trial.
    Vaccine. 2025;62:127559.
    PubMed         Abstract available

  89. GENOVA P, Phung CF, Dickens BL, Lim JM, et al
    Trust in government, science, and vaccine confidence in Southeast Asia: A latent profile analysis.
    Vaccine. 2025;62:127536.
    PubMed         Abstract available

  90. FEDELE G, Schiavoni I, Trentini F, Leone P, et al
    Six-month follow-up of antibody response to bivalent mRNA SARS-CoV-2 vaccine booster in healthcare workers.
    Vaccine. 2025;62:127524.
    PubMed         Abstract available

  91. CHEMAITELLY H, Ayoub HH, Coyle P, Tang P, et al
    Comparative effectiveness of one versus two doses of COVID-19 vaccines in Qatar: Evidence of converging protection over time.
    Vaccine. 2025;62:127556.
    PubMed         Abstract available

  92. KANG Y, Zhang F, Vogt TM
    Parental attitudes, beliefs, and experiences related to pediatric COVID-19 vaccination.
    Vaccine. 2025;62:127043.
    PubMed         Abstract available

  93. DIRAY-ARCE J, Chang AC, Moradipoor S, Amodio D, et al
    Longitudinal Meta-cohort study protocol using systems biology to identify vaccine safety biomarkers.
    Vaccine. 2025;62:127504.
    PubMed         Abstract available

  94. XU S, Sy LS, Hong V, Qian L, et al
    Tinnitus risk after COVID-19 XBB.1.5 vaccination: A self-controlled case series study.
    Vaccine. 2025;62:127548.
    PubMed         Abstract available

  95. SALOMAO MDG, de Almeida Leitao Curimbaba C, Braga PE, Franca JID, et al
    Long-term efficacy and immune response of CoronaVac in Brazilian health care workers: Insights from PROFISCOV unblinded trial.
    Vaccine. 2025;62:127527.
    PubMed         Abstract available

  96. VAN DER WEG W, von Kreijfelt G, Davidson L, Zwaveling J, et al
    Strengthening spontaneous reporting-based signal detection during a pandemic with cases from electronic health records using a natural language processing tool.
    Vaccine. 2025;62:127549.
    PubMed         Abstract available

  97. ANDERSEN KM, Ahi T, Mateus JS, Yu T, et al
    2024-2025 BNT162b2 COVID-19 vaccine effectiveness in non-immunocompromised adults: mid-season estimates from vaccine registries in two states linked to administrative claims.
    Vaccine. 2025;62:127534.
    PubMed         Abstract available

  98. SAIAG E, Shalit R, Alcalay Y, Hasday I, et al
    Cellular and humoral immune responses to SARS-CoV2, comparing previously infected individuals who received one vaccine dose to uninfected individuals after three vaccine doses: A case-control study.
    Vaccine. 2025;62:127525.
    PubMed         Abstract available

  99. PERESON MJ, Badano MN, Sabbione F, Keitelman I, et al
    Evaluation of T cell immune memory response after BBIBP-CorV, gam-COVID-Vac, and heterologous gam-COVID-Vac /mRNA-1273 COVID-19 vaccination schemes against different SARS-CoV-2 variants.
    Vaccine. 2025;62:127526.
    PubMed         Abstract available

  100. VISKUPIC F, Wiltse DL, Djira G
    RSV vaccine uptake among seniors: A path analysis approach.
    Vaccine. 2025;62:127505.
    PubMed         Abstract available

  101. SHETTY AN, Kattan GS, Javed M, Pearce C, et al
    Validating community concerns of menstrual changes associated with COVID-19 vaccination using a self-controlled case series analysis of real-world data.
    Vaccine. 2025;62:127511.
    PubMed         Abstract available

  102. DALEXIS RD, Muray M, Kibret TC, Farahi SMMM, et al
    Factors related to COVID-19 vaccine effectiveness perception in racially diverse adults in Canada.
    Vaccine. 2025;62:127498.
    PubMed         Abstract available

  103. DIONNE M, Sauvageau C, Ward JK, Sylvain-Morneau J, et al
    COVID-19 vaccine hesitancy and perceived post-vaccination adverse event: Findings from a cross-sectional survey.
    Vaccine. 2025;62:127529.
    PubMed         Abstract available

  104. MUNOZ FM, Kampmann B, Stergachis A, Chaudhary M, et al
    A template tool for the evaluation of vaccines for emerging pathogens to be used for pregnant and breast-feeding women.
    Vaccine. 2025;62:127513.
    PubMed         Abstract available

  105. GWAK E, Choe SA, Kim K, Bolormaa E, et al
    Real-world effectiveness of NVX-CoV2373 and BNT162b2 mRNA COVID-19 vaccination in South Korea.
    Vaccine. 2025;62:127496.
    PubMed         Abstract available

  106. GASHTI AB, Patel M, Chahal PS, Hrapovic S, et al
    Purification and functional characterization of gag-spike virus-like particles: Process optimization for efficient vaccine production.
    Vaccine. 2025;62:127500.
    PubMed         Abstract available

  107. BROAD J, Letley L, Adair G, Walker J, et al
    An England-wide survey on attitudes towards antenatal and infant immunisation against respiratory syncytial virus amongst pregnant and post-partum women.
    Vaccine. 2025;62:127482.
    PubMed         Abstract available

  108. GREENBERG BM, Minna JD, Gerber DE, Hernandez RS, et al
    SARS-CoV-2 vaccine failure rates and predictors of immune response in a diverse immunocompromised patient population.
    Vaccine. 2025;62:127473.
    PubMed         Abstract available

  109. MOHANTY S, Zurovac J, Barna M, Cossrow N, et al
    Changes in pneumococcal vaccination disparities by area-level social vulnerability during the COVID-19 pandemic among Medicare and Medicaid enrollees.
    Vaccine. 2025;62:127452.
    PubMed         Abstract available

  110. LIN J, Dai Z, Li C, He WQ, et al
    Change in herpes zoster vaccination uptake before and during the COVID-19 pandemic in the United States older adults.
    Vaccine. 2025;62:127503.
    PubMed         Abstract available

  111. ZLOTNICK C, Castel OC
    The predictors of full, partial and no COVID-19 vaccination among immigrants and non-immigrants.
    Vaccine. 2025;62:127484.
    PubMed         Abstract available

  112. MURATA M, Matsumoto Y, Shimono N
    Comparison of SARS-CoV-2 antibody responses following the second dose of BNT162b2 and mRNA-1273 vaccines in people living with HIV-1.
    Vaccine. 2025;62:127457.
    PubMed         Abstract available

  113. WAGNER SB, Rincon M, Keen KE, Hawk GS, et al
    SARS-CoV-2 breakthrough infection during pregnancy preferentially elicits IgG4 response and enhanced placental-transfer.
    Vaccine. 2025;62:127476.
    PubMed         Abstract available

  114. SANO K, Miyakawa K, Kato H, Kimura Y, et al
    Neutralizing antibody evasion of SARS-CoV-2 JN.1 derivatives KP.3, KP.3.1.1, LB.1, and XEC.
    Vaccine. 2025;62:127472.
    PubMed         Abstract available

  115. ABEL ZDV, Roope LSJ, Violato M, Clarke PM, et al
    Accuracy of online surveys in predicting COVID-19 uptake and demand: A cohort study investigating vaccine sentiments and switching in 13 countries from 2020 to 2022.
    Vaccine. 2025;62:127450.
    PubMed         Abstract available

  116. BAUSSANO I, Tenet V, Baghdasarova K, Harutyunyan Z, et al
    HPV burden in Armenia among unvaccinated women: a series of cross-sectional population-based prevalence surveys.
    Vaccine. 2025;62:127405.
    PubMed         Abstract available

  117. SPRACKLEN TF, Day J, Van Der Ross H, Butters C, et al
    Humoral, T cell and immune gene expression responses to SARS-CoV-2 vaccination in a small group of children with previous MIS-C.
    Vaccine. 2025;62:127461.
    PubMed         Abstract available

  118. SCHMITT MM, Rossler A, Netzl A, Knabl L, et al
    Exposure to two antigenically distinct SARS-CoV-2 variants broadens neutralization patterns.
    Vaccine. 2025;62:127459.
    PubMed         Abstract available

  119. MIHIN HUSKIC I, Bensic M, Kretonic K, Miskulin I, et al
    Duration of protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after primary homologous vaccination or first infection.
    Vaccine. 2025;62:127440.
    PubMed         Abstract available

  120. CUTLAND CL, Gutu K, Yun JA, Izu A, et al
    Lessons learnt during establishment of COVID-19 active vaccine safety surveillance in nine African countries.
    Vaccine. 2025;62:127441.
    PubMed         Abstract available

Friday, September 19, 2025

RAPID #RISK #ASSESSMENT: #EBOLA VIRUS DISEASE, DRC (#WHO, September 19 '25)

 


{Summary}

Overall risk and confidence

Overall risk

-- National: High 

-- Regional: Moderate   

-- Global: Low   

Confidence in available information 

-- National: Moderate

-- Regional: Moderate

-- Global: Moderate


Risk statement

On 1 September 2025, WHO received an alert from the Ministry of Health of the Democratic Republic of the Congo (DRC) regarding suspected cases of Ebola virus disease (EVD) in the Bulape Health Zone, Kasai Province, DRC. 

The first currently known suspected EVD case was admitted to the Bulape General Reference Hospital on 20 August 2025 and reported to have died five days later (25 August 2025).

This is a 34-year-old female patient with a 34-week gestational age who presented with fever, bloody diarrhoea, followed by anal, oral, and nasal haemorrhage, vomiting, and asthenia

She reportedly died on 25 August 2025, with a clinical picture of multiple organ failure. 

Two of the contacts of this first case (a midwife and a laboratory technician) also developed similar symptoms and died a few days later.  

As of 4 September 2025, a total of 28 suspected cases, including 15 deaths (case fatality ratio: 54 %) had been reported from the Bulape health zone (Bulape, Bulape COM and Dikolo) and Mweka health zone. 

Among deaths, four are health care workers.  

In addition, 20% of the suspected cases are aged under 15 years

Five blood samples and one swab were collected from six suspected cases from the three health areas and arrived today at the National Public Health Laboratory (INRB) in Kinshasa for confirmation testing.

A crisis committee has been activated at the local and provincial levels, risk communication and active surveillance activities are underway, all cases are isolated, Infection Prevention and Control (IPC) measures are being implemented, isolation and contact tracing are underway, and patients are receiving intravenous medications, including ceftriaxone and metronidazole

The INRB confirmed Ebola virus (EBOV), Orthoebolavirus zairense species was detected through RTPCR assays, including GeneXpert, on 3 September.    

At national level, the risk is considered high due to:  

Information gaps on the cases, including the first case, particularly: 

-- the date of symptom onset, 

-- their therapeutic itinerary, 

-- the potential number of contacts within the community, and 

-- epidemiological links between cases does not allow an assessment as to the extent of the outbreak. Similar alerts have been reported from this location/region in the past few months.  

Most of the cases recorded so far in this health zone live in the Health Areas with a high population density and mobility. This could accelerate disease transmission within the community.  

The last EVD outbreak in this health zone, Bulape, was in 2007, 18 years later, the capacities required for the response to a potential EVD outbreak may not exist.  

So far, in addition to Bulape health zone, the epicentre of the outbreak, suspected cases are being reported in the neighbouring district of Mweka showing a potential geographic extension of the outbreak.   

Bulape has a large market every Friday, attracting people from the surrounding villages. The city of Mweka borders a health district in the province of Kasai-Central (Bena Leka). Furthermore, population movements between Bulape and Tshikapa, the capital city of Kasai province, are frequent as part of trading activities.  Tshikapa city is considered as a regional market hub receiving populations from neighbouring provinces.  

At the regional level the risk is moderate due to the proximity of Bulape to Tshikapa city, the capital city of Kasai province and the Angolan border (approximately 100 to 200 kilometres depending on the nearest border crossing point) as well as population movement between Bulape and Tshikapa then Tshikapa and Angola.  

At the global level, the risk is low

(...)

Source: World Health Organization, https://www.who.int/publications/m/item/who-rapid-risk-assessment---ebola-virus-disease--democratic-republic-of-the-congo-v.1

____

#Syndromic approach for rapid #detection and differentiation of #human pathogenic #alphaviruses

 


Highlights

• Most vector-borne viruses like alphaviruses are not included in routine diagnostics

• Lack of testing results in misdiagnoses and underdetection

• A new multiplexed real-time PCR assay detects all human pathogenic alphaviruses

• The new multiplex assay is more sensitive than available tests and highly specific

• The multiplex test can be applied broadly for diagnostics and molecular surveillance


Abstract

Background

Knowledge of epidemiology, pathogenesis, and public health burden is scarce for many arthropod-borne viruses (arboviruses). Insufficient knowledge is partly due to lack of exhaustive laboratory diagnostics due to resource limitations. Among arboviruses, arthritogenic and encephalitogenic alphaviruses are globally widespread, can cause severe disease, and can co-occur regionally.

Objectives

We developed and validated a multiplexed real-time reverse transcription-PCR assay for the detection of all alphaviruses commonly causing human disease except Barmah Forest virus.

Study design

The assay combines five antigenic complex-specific assays and one Chikungunya virus-specific assay in a single parallelized reaction.

Results

Comparisons with previously published PCR-based protocols for broad alphavirus detection using 20 different human-pathogenic alphaviruses revealed a significantly higher sensitivity of the new multiplexed assay (Fisher’s exact test, p<0.0001). Detection limits with the new assay ranged from 0.83 cps/μl of extracted O’nyong-nyong virus to 33.05 cps/μl of extracted Western equine encephalitis virus. Antigenic complexes could be clearly differentiated by reactivity, Ct values (T-test, p<0.0025) and signal intensities (T-test, p<0.0001), even when testing high alphavirus concentrations potentially capable of causing false-positive PCR results. Testing of high-titred cell culture supernatants of eight important non-alphaviral arboviruses, of 4,308 serum samples collected from febrile patients in Benin and Peru, of seven CHIKV positive diagnostic samples from Brazil, and of non-targeted alphaviruses confirmed excellent diagnostic performance by the new assay, including improved detection of Mayaro and Venezuelan equine encephalitis virus in clinical specimens.

Conclusions

Short turn-around time, applicability in resource-limited settings, antigenic complex determination, and higher sensitivity compared to previously available tests make the new assay a useful tool for alphavirus surveillance and routine patient diagnostics.

Source: Journal of Clinical Virology, https://www.sciencedirect.com/science/article/pii/S1386653225001143?dgcid=rss_sd_all

____

#Modeling and #Analysis of SIRR Model (#Ebola #Transmission Dynamics Model) with Delay Differential Equation

 


Abstract

Background

Ebola virus disease (EVD) is a severe and often fatal illness with high transmission potential and recurring outbreaks. Traditional compartmental models often neglect biologically important delays, such as the latent period before an infected individual becomes infectious, limiting their ability to capture real-world epidemic patterns. Including such delays can provide a more accurate understanding of outbreak persistence and control strategies.

Methods

In this study, we develop and analyze a novel deterministic SIRR model that captures the complex transmission dynamics of Ebola by explicitly combining nonlinear incidence rates with a delay differential equation framework. Unlike traditional models, this approach integrates a biologically motivated delay to represent the latent period before infectiousness, providing a more realistic depiction of disease spread. The basic reproduction number (R0) is derived using the next-generation matrix, and local stability for disease-free and endemic equilibria is established. Using center manifold theory, we investigate transcritical bifurcation at R0 = 1, while Hopf bifurcation analysis determines when delays trigger oscillatory epidemics. Sensitivity analysis identifies parameters most influencing R0, and numerical simulations are performed using the fourth-order Runge–Kutta method.

Results

The main novelty of this work lies in its detailed investigation of how delays influence outbreak persistence and can trigger oscillatory epidemics, patterns often observed in practice but rarely captured by classic models. For R0< 1, the disease-free equilibrium is locally asymptotically stable; for R0> 1, an endemic equilibrium emerges. Increasing delays destabilizes the system, amplifying peak infections, prolonging outbreaks, and producing sustained oscillations. Isolation of recovered individuals (c) significantly reduces R_0, while transmission rate (β), recruitment rate (Λ), and isolation transition rate (ρ) are identified as the most sensitive parameters.

Conclusions

Accounting for delayed recovery dynamics is crucial for accurately predicting outbreak patterns and designing effective interventions. This delay-based, nonlinear-incidence model offers a robust analytical and computational framework for guiding public health strategies, with direct implications for reducing transmission, shortening outbreak duration, and preventing epidemic resurgence.

Source: F1000 Research, https://f1000research.com/articles/14-857/v1

____

#USA, #Wastewater Data for Avian #Influenza #H5 (CDC, September 19 '25)

 


{Summary}

Time Period: September 07, 2025 - September 13, 2025

-- H5 Detection3 sites (0.7%)

-- No Detection401 sites (99.3%)

-- No samples in last week57 sites




(...)

Source: US Centers for Disease Control and Prevention, https://www.cdc.gov/nwss/rv/wwd-h5.html

____

Intensive #reassortment and frequent #intercontinental #transmission revealed by long-term genetic analysis of #H10 avian #influenza viruses in #Taiwan

 


ABSTRACT

H10 subtype avian influenza viruses primarily circulate among wild waterfowl but can occasionally infect mammals, including humans, and recent sporadic human cases have raised significant public health concerns. In this study, we sequenced and analysed 59 H10 subtype viruses isolated from wild birds in Taiwan. Results showed that all isolates were genetically distinct from human and other mammalian H10 subtype isolates. Taiwanese isolates exhibited high genetic diversity and could be categorized into 34 distinct genotypes, with each genotype circulating only in a single migratory season and not recurring during subsequent seasons. Additional analyses revealed that certain gene pools frequently circulate in the Pacific Rim, with evidence of North American lineage genes establishing long-term populations in Eurasia and vice versa. Although no characteristics indicative of mammalian adaptation was found in the Taiwanese isolates, temporal changes in the haemagglutinin cleavage site sequences were observed. This study provides a comprehensive overview of the evolutionary dynamics of H10 avian influenza viruses isolated from wild birds in Taiwan, emphasizing the complexity of intercontinental gene flow and viral reassortment. Currently, no consistent molecular markers indicating the impact of H10 avian influenza viruses on mammals or poultry have been identified. Notably, the observed changes in the haemagglutinin cleavage site sequences among Eurasian viruses suggest potential antigenic variations, indicating a need for further investigation into these changes. This potential highlights the necessity of ongoing surveillance to track the evolution and transmission dynamics of these viruses.

Source: Emerging Microbes and Infections, https://www.tandfonline.com/doi/full/10.1080/22221751.2025.2556794#abstract

____

Thursday, September 18, 2025

#Italy, Integrated #Surveillance for #WNV & #USUV - Weekly Bulletin No. 10, 18 September '25 (Summary)

 


{Summary}

-- During current epidemiological week (11– 17 September 2025), 65 new confirmed human cases of infection with West Nile Virus have been reported. 

-- The total number of confirmed cases, since the beginning of the epidemic season, has thus risen to 647 (it was 582 last week), of these: 

- 300 were West Nile Neuroinvasive Disease (WNND): 15 in Piedmont, 39 Lombardy, 24 Veneto, 2 Friuli-Venezia Giulia, 1 Liguria, 23 Emilia-Romagna, 5 Tuscany, 83 Latium, 2 Molise, 77 Campania, 2 Apulia, 2 Basilicata, 5 Calabria, 1 Sicily, 19 Sardinia, 

- 54 were asymptomatic cases detected among blood donors

- 284 were West Nile Fever cases (one imported from Kenya), 

- 3 asymptomatic cases and 

- 6 unspecified casese. 

-- Among confirmed cases, there were 47 death cases: 7 in Piedmont, 5 Lombardy, 1 Emilia-Romagna, 16 Latium, 15 Campania, 2 Calabria, 1 Sardinia. 

- The Case-Fatality Rate in WNND cases was 15.8% (it was 20% in 2018 and  14% in 2024). 

-- This week nine confirmed cases of Usutu Virus infection have been reported: 2 in Piedmont, 2 Lombardy, 2 Veneto, 3 Latium.

(...)

Source: High Institute of Health, https://www.epicentro.iss.it/westnile/bollettino/Bollettino_WND_2025_10.pdf

____

My New Space

Most Popular Posts